Your email has been successfully added to our mailing list.

×
0 0 -0.0357142857142857 -0.0535714285714287 -0.103571428571429 -0.05 0.0285714285714286 -0.00871428571428571
Stock impact report

ASLAN Pharma down 45% premarket on pricing equity offering [Seeking Alpha]

ASLAN Pharmaceuticals Ltd ADS (ASLN)  More Company Research Source: Seeking Alpha
US:NASDAQ Investor Relations: ir.aslanpharma.com
PDF ASLAN Pharma down 45% premarket on pricing equity offering ASLAN Pharmaceuticals (NASDAQ: ASLN priced Underwriters' over-allotment is an additional 768,679 ADSs. Net proceeds will be used to fund the clinical development of ASLAN004 and ASLAN003 and for general corporate purposes. Closing date is December 5. Shares are down 45% Previously: ASLAN Pharma launches equity offering [Read more]
Impact snapshot Event time: ASLN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
ASLN alerts
from News Quantified
Opt-in for
ASLN alerts

from News Quantified
Opt-in for
ASLN alerts

from News Quantified